227 related articles for article (PubMed ID: 20504346)
1. Expression signatures of TP53 mutations in serous ovarian cancers.
Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
[TBL] [Abstract][Full Text] [Related]
2. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
3. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W
Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293
[TBL] [Abstract][Full Text] [Related]
7. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
8. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
[TBL] [Abstract][Full Text] [Related]
10. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
11. Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous?
Nakayama T; Ling ZQ; Mukaisho K; Hattori T; Sugihara H
BMC Cancer; 2010 Jun; 10():311. PubMed ID: 20565940
[TBL] [Abstract][Full Text] [Related]
12. TP53 Mutations in Breast and Ovarian Cancer.
Silwal-Pandit L; Langerød A; Børresen-Dale AL
Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27815305
[TBL] [Abstract][Full Text] [Related]
13. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
Berchuck A; Iversen ES; Luo J; Clarke JP; Horne H; Levine DA; Boyd J; Alonso MA; Secord AA; Bernardini MQ; Barnett JC; Boren T; Murphy SK; Dressman HK; Marks JR; Lancaster JM
Clin Cancer Res; 2009 Apr; 15(7):2448-55. PubMed ID: 19318476
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
Tuna M; Ju Z; Yoshihara K; Amos CI; Tanyi JL; Mills GB
Br J Cancer; 2020 Feb; 122(3):405-412. PubMed ID: 31780779
[TBL] [Abstract][Full Text] [Related]
15.
Na K; Sung JY; Kim HS
Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
[TBL] [Abstract][Full Text] [Related]
16. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
18. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.
Seagle BL; Eng KH; Dandapani M; Yeh JY; Odunsi K; Shahabi S
Oncotarget; 2015 Jul; 6(21):18641-52. PubMed ID: 26215675
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
Devor EJ; Gonzalez-Bosquet J; Warrier A; Reyes HD; Ibik NV; Schickling BM; Newtson A; Goodheart MJ; Leslie KK
Int J Oncol; 2017 May; 50(5):1721-1728. PubMed ID: 28339050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]